Hua Medicine announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED, (also known as HMM0301). The following findings from the SEED study were presented in oral and symposium presentations at the American Diabetes Association’s 80th Scientific Session digitally: Fast on-set of action (effective HbA1c reduction in 4 weeks); Significant improvement of ß-cell function in treatment group as compared to the placebo group; Significant reduction of 2-hour post-prandial glucose reduction was observed in treatment group as compared to the placebo group; Good safety profile and tolerance of dorzagliatin with limited hypoglycemia and similar incidence of adverse events between the treatment and placebo groups; Sustained efficacy over 24 weeks; and Good response rate. Dorzagliatin shows improvements in marker that measure ß-cell function: Data demonstrates that there was significant ß-cell function improvement (as measured by HOMA2-ß1) in the treatment group versus the placebo group – an increase of 2.56% vs. a decline of 0.72% in ß-cell function improvement. In the trial, Dorzagliatin exhibits positive impact on blood glucose control with a good safety profile: The post-analysis of Phase III monotherapy results show that dorzagliatin exhibits several promising characteristics for Type 2 diabetes treatment. Dorzagliatin achieved a statistically significant reduction of blood glucose - 1.07% reduction in HbA1c from baseline; Significant 2-hour post-prandial glucose reduction was observed (-2.83mmol/L vs -0.50mmol/L, p<0.001); Patients saw fast on-set of blood glucose reduction during the first follow-up visit after initiation of treatment; Hypoglycemia was very mild (1 incidence out of 310 patients in the treatment group over 24-week period); and Other incidences of adverse events were similar between the treatment and placebo groups. Note 1: The HOMA, Homeostatic Model Assessment, is a computer model to evaluate the beta cell function and insulin resistance in clinical studies that was developed in 1985. It is used to estimate the insulin sensitivity and beta cell function based on fasting glucose and insulin or c-peptide. HOMA2 is a computer model advance from HOMA1 and includes the factors of hepatic and peripheral insulin resistance, a physiological measure of glucose homeostasis.